

# Sarah C Markt, Scd

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8556762/publications.pdf>

Version: 2024-02-01

83  
papers

1,329  
citations

279798

23  
h-index

395702

33  
g-index

84  
all docs

84  
docs citations

84  
times ranked

2329  
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluating Factors Associated With Continuous Glucose Monitoring Utilization With the Type 1 Diabetes Exchange Registry. <i>Journal of Diabetes Science and Technology</i> , 2023, 17, 1580-1589.	2.2	2
2	Sociodemographic and clinical factors associated with receipt of biomarker testing in patients with metastatic colorectal cancer. <i>Cancer Medicine</i> , 2023, 12, 1850-1859.	2.8	3
3	Prostate Cancer Screening and Young Black Men: Can Early Communication Avoid Later Health Disparities?. <i>Journal of Cancer Education</i> , 2022, 37, 1460-1465.	1.3	6
4	Weight loss during neoadjuvant therapy for pancreatic cancer does not predict poor outcomes. <i>American Journal of Surgery</i> , 2022, 223, 927-932.	1.8	4
5	Black race is independently associated with underutilization of transplantation for clinical T1 hepatocellular carcinoma. <i>Hpb</i> , 2022, 24, 925-932.	0.3	1
6	The Impact of Race and Sex on Metastatic Bladder Cancer Survival. <i>Urology</i> , 2022, 165, 98-105.	1.0	4
7	A nationwide analysis of pancreatic cancer trial enrollment reveals disparities and participation problems. <i>Surgery</i> , 2022, 172, 257-264.	1.9	9
8	Weight Tracking as a Novel Prognostic Marker After Pancreatectomy. <i>Annals of Surgical Oncology</i> , 2022, 29, 3450-3459.	1.5	6
9	ASO Author Reflection: Post-pancreatectomy Weight Trends Predict Recurrence and Survival. <i>Annals of Surgical Oncology</i> , 2022, , 1.	1.5	1
10	Finding a Place for Family History To Inform High-grade Prostate Cancer Risk. <i>European Urology</i> , 2022, , .	1.9	0
11	ASO Visual Abstract: Weight Tracking as a Novel Prognostic Marker After Pancreatectomy. <i>Annals of Surgical Oncology</i> , 2022, 29, 3462-3462.	1.5	2
12	Characterization and functional analysis of microbiome in bladder cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 541-541.	1.6	2
13	Characterization of fungal mycobiome in bladder cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 542-542.	1.6	0
14	Excess cancer prevalence in men with HIV: A nationwide analysis of Medicaid data. <i>Cancer</i> , 2022, 128, 1987-1995.	4.1	9
15	Incidence of Kidney Stones in the United States: The Continuous National Health and Nutrition Examination Survey. <i>Journal of Urology</i> , 2022, 207, 851-856.	0.4	55
16	Urinary 6-sulfatoxymelatonin Levels and Prostate Cancer Risk among Men in the Multiethnic Cohort. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 688-691.	2.5	1
17	Racial Disparities in Prostate Cancer: Evaluation of Diet, Lifestyle, Family History, and Screening Patterns. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 982-990.	2.5	6
18	Association Between Operative Approach and Venous Thromboembolism Rate Following Hepatectomy: a Propensity-Matched Analysis. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 2778-2787.	1.7	7

#	ARTICLE	IF	CITATIONS
19	Gender Disparities in Bladder Cancer-Specific Survival in High Poverty Areas Utilizing Ohio Cancer Incidence Surveillance System (OCISS). <i>Urology</i> , 2021, 151, 163-168.	1.0	4
20	Recommended Definitions of Aggressive Prostate Cancer for Etiologic Epidemiologic Research. <i>Journal of the National Cancer Institute</i> , 2021, 113, 727-734.	6.3	36
21	Female Authorship Trends in Urology During the COVID-19 Pandemic. <i>European Urology</i> , 2021, 79, 322-324.	1.9	5
22	“Robotic fatigue” The impact of case order on positive surgical margins in robotic-assisted laparoscopic prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 365.e17-365.e23.	1.6	3
23	Reassessing the role of surgery in the elderly or chronically sick with proximal extrahepatic cholangiocarcinoma. <i>Surgery</i> , 2021, 169, 233-239.	1.9	5
24	ASO Author Reflections: Prediagnosis Weight Loss: Early Detection and Postoperative Prognosis Among Patients with Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 6293-6293.	1.5	1
25	Weight Loss as an Untapped Early Detection Marker in Pancreatic and Periapillary Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 6283-6292.	1.5	28
26	Exploratory assessment of pineal gland volume, composition, and urinary 6-sulfatoxymelatonin levels on prostate cancer risk. <i>Prostate</i> , 2021, 81, 487-496.	2.3	3
27	Immunotherapy Is Associated with a Survival Benefit in Patients Receiving Chemotherapy for Metastatic Pancreatic Cancer. <i>Journal of Pancreatic Cancer</i> , 2021, 7, 31-38.	0.9	2
28	A polymorphism in the promoter of FRAS1 is a candidate SNP associated with metastatic prostate cancer. <i>Prostate</i> , 2021, 81, 683-693.	2.3	5
29	Unintentional Weight Loss as a Marker of Malignancy Across Body Weight Categories. <i>Current Cardiovascular Risk Reports</i> , 2021, 15, 1.	2.0	0
30	Abstract 863: Circadian gene expression in metastatic sites and association with survival in metastatic castration-resistant prostate cancer. , 2021, , .		0
31	Facility volume-survival relationship in patients with early-stage pancreatic adenocarcinoma treated with neoadjuvant chemotherapy followed by pancreatoduodenectomy. <i>Surgery</i> , 2021, 170, 207-214.	1.9	19
32	Data Matching to Support Analysis of Cancer Epidemiology Among Veterans Compared With Non-Veteran Populations—An Exemplar in Brain Tumors. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 985-994.	2.1	2
33	Statin Use Is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1086-1093.	7.0	35
34	Sleep quality and prostate cancer aggressiveness: Results from the REDUCE trial. <i>Prostate</i> , 2020, 80, 1304-1313.	2.3	8
35	The impact of hormones and reproductive factors on the risk of bladder cancer in women: results from the Nurses’ Health Study and Nurses’ Health Study II. <i>International Journal of Epidemiology</i> , 2020, 49, 599-607.	1.9	10
36	Baldness and Risk of Prostate Cancer in the Health Professionals Follow-up Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1229-1236.	2.5	5

#	ARTICLE	IF	CITATIONS
37	Patient-centered Weight Tracking as an Early Cancer Detection Strategy. <i>Journal of Cancer Prevention</i> , 2020, 25, 181-188.	2.0	5
38	Three Fold Risk of Atrial Fibrillation in Ibrutinib Treated CLL Patients without Increased Risk of Stroke: A SEER-Medicare Database Analysis. <i>Blood</i> , 2020, 136, 18-19.	1.4	3
39	Association of Inherited Pathogenic Variants in Checkpoint Kinase 2 ( <i>CHEK2</i> ) With Susceptibility to Testicular Germ Cell Tumors. <i>JAMA Oncology</i> , 2019, 5, 514.	7.1	43
40	Body Mass Index and Outcomes in Germ-Cell Tumors. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 283-290.	1.9	2
41	Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men. <i>European Urology</i> , 2019, 75, 399-407.	1.9	43
42	Single-nucleotide polymorphisms in DNMT3B gene and DNMT3B mRNA expression in association with prostate cancer mortality. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 284-291.	3.9	4
43	A Prospective Study of the Association between Physical Activity and Risk of Prostate Cancer Defined by Clinical Features and TMPRSS2:ERG. <i>European Urology</i> , 2019, 76, 33-40.	1.9	26
44	Autologous Stem-Cell Transplantation Outcomes for Relapsed Metastatic Germ-Cell Tumors in the Modern Era. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 58-64.e1.	1.9	7
45	Association between <i>Trichomonas vaginalis</i> and prostate cancer mortality. <i>International Journal of Cancer</i> , 2019, 144, 2377-2380.	5.1	21
46	Geographic Differences in Baseline Prostate Inflammation and Relationship with Subsequent Prostate Cancer Risk: Results from the Multinational REDUCE Trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 783-789.	2.5	1
47	Sex differences in the associations of obstructive sleep apnoea with epidemiological factors. <i>European Respiratory Journal</i> , 2018, 51, 1702421.	6.7	72
48	Reply to Christian D. Fankhauser, Nico C. Grossmann, Joerg Beyer, and Thomas Hermanns Letter to the Editor re: Sophia C. Kamran, Thomas Seisen, Sarah C. Markt, et al. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. <i>Eur Urol</i> 2018;73:262-70. <i>European Urology</i> , 2018, 73, e96-e97.	1.9	0
49	Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. <i>European Urology</i> , 2018, 73, 262-270.	1.9	20
50	Smoking and Disease Outcomes in Patients With Malignant Germ Cell Tumors. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 78-84.	1.9	4
51	Height, Obesity, and the Risk of TMPRSS2:ERG-Defined Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 193-200.	2.5	18
52	Reply to Aditya Bagrodia, Solomon Woldu, David F. Penson, Alexander Kutikov, and Samuel D. Kaffenberger's Letter to the Editor re: Sophia C. Kamran, Thomas Seisen, Sarah C. Markt, et al. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. <i>Eur Urol</i> 2018;73:262-70. <i>European Urology</i> , 2018, 73, e100-e101.	1.9	1
53	Midlife metabolic factors and prostate cancer risk in later life. <i>International Journal of Cancer</i> , 2018, 142, 1166-1173.	5.1	18
54	Smoking cessation among men following cancer diagnosis: a matched cohort study. <i>Journal of Cancer Survivorship</i> , 2018, 12, 786-793.	2.9	8

#	ARTICLE	IF	CITATIONS
55	Family History of Breast or Prostate Cancer and Prostate Cancer Risk. <i>Clinical Cancer Research</i> , 2018, 24, 5910-5917.	7.0	52
56	Early-Life Alcohol Intake and High-Grade Prostate Cancer: Results from an Equal-Access, Racially Diverse Biopsy Cohort. <i>Cancer Prevention Research</i> , 2018, 11, 621-628.	1.5	15
57	Insurance status and cancer treatment mediate the association between race/ethnicity and cervical cancer survival. <i>PLoS ONE</i> , 2018, 13, e0193047.	2.5	41
58	Age ≥40 Years Is Associated with Adverse Outcome in Metastatic Germ Cell Cancer Despite Appropriate Intended Chemotherapy. <i>European Urology Focus</i> , 2017, 3, 621-628.	3.1	10
59	Inherited variation in circadian rhythm genes and risks of prostate cancer and three other cancer sites in combined cancer consortia. <i>International Journal of Cancer</i> , 2017, 141, 1794-1802.	5.1	28
60	A Walking Intervention Among Men With Prostate Cancer: A Pilot Study. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e1021-e1028.	1.9	20
61	Authors' reply to Rishniw. <i>BMJ: British Medical Journal</i> , 2017, 357, j2910.	2.3	0
62	Post-orchietomy adjuvant therapy versus surveillance for stage IS testicular cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 406-406.	1.6	0
63	Snus use, smoking and survival among prostate cancer patients. <i>International Journal of Cancer</i> , 2016, 139, 2753-2759.	5.1	27
64	Insurance status and disparities in disease presentation, treatment, and outcomes for men with germ cell tumors. <i>Cancer</i> , 2016, 122, 3127-3135.	4.1	46
65	Pineal Gland Volume Assessed by MRI and Its Correlation with 6-Sulfatoxymelatonin Levels among Older Men. <i>Journal of Biological Rhythms</i> , 2016, 31, 461-469.	2.6	26
66	CHALLENGE Trial 1 Year Feasibility Results Letter. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1277-1277.	2.5	0
67	Sleep disruption, chronotype, shift work, and prostate cancer risk and mortality: a 30-year prospective cohort study of Finnish twins. <i>Cancer Causes and Control</i> , 2016, 27, 1361-1370.	1.8	79
68	Sniffing out significant $P$ values genome wide association study of asparagus anosmia. <i>BMJ, The</i> , 2016, 355, i6071.	6.0	11
69	Alcohol intake, drinking patterns, and prostate cancer risk and mortality: a 30-year prospective cohort study of Finnish twins. <i>Cancer Causes and Control</i> , 2016, 27, 1049-1058.	1.8	30
70	Dietary lycopene intake and risk of prostate cancer defined by ERG protein expression. <i>American Journal of Clinical Nutrition</i> , 2016, 103, 851-860.	4.7	65
71	Sleep Duration and Disruption and Prostate Cancer Risk: a 23-Year Prospective Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 302-308.	2.5	41
72	ABO blood group alleles and prostate cancer risk: Results from the breast and prostate cancer cohort consortium (BPC3). <i>Prostate</i> , 2015, 75, 1677-1681.	2.3	14

#	ARTICLE	IF	CITATIONS
73	Insufficient Sleep and Risk of Prostate Cancer in a Large Swedish Cohort. <i>Sleep</i> , 2015, 38, 1405-1410.	1.1	35
74	Urinary Melatonin Levels, Sleep Disruption, and Risk of Prostate Cancer in Elderly Men. <i>European Urology</i> , 2015, 67, 191-194.	1.9	74
75	Circadian clock genes and risk of fatal prostate cancer. <i>Cancer Causes and Control</i> , 2015, 26, 25-33.	1.8	39
76	Association of age 40 and older with adverse outcome in metastatic testicular cancer (TC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 386-386.	1.6	0
77	BMI at diagnosis and adverse outcomes among men with malignant testicular germ cell tumors.. <i>Journal of Clinical Oncology</i> , 2015, 33, 400-400.	1.6	0
78	Sunlight and testicular germ cell tumor rates in the USA.. <i>Journal of Clinical Oncology</i> , 2015, 33, e15565-e15565.	1.6	0
79	Melanoma risk in men with testicular germ cell tumors in the United States.. <i>Journal of Clinical Oncology</i> , 2015, 33, e15554-e15554.	1.6	0
80	5 $\alpha$ -Reductase Inhibitors and Risk of High-Grade or Lethal Prostate Cancer. <i>JAMA Internal Medicine</i> , 2014, 174, 1301.	5.1	38
81	Genetic variation across C-reactive protein and risk of prostate cancer. <i>Prostate</i> , 2014, 74, 1034-1042.	2.3	14
82	Circadian dysrhythm and advanced prostate cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 199-199.	1.6	0
83	HPV16 Seropositivity and Subsequent HPV16 Infection Risk in a Naturally Infected Population: Comparison of Serological Assays. <i>PLoS ONE</i> , 2013, 8, e53067.	2.5	39